Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation
NCT06740786Not yet recruiting
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Randomised trial of dapagliflozin in Atrial fibrillation (AFib) (2 arms). Primary endpoint: Recurrence of atrial arrhythmias at 12 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06740786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740786.